

# Genetics of Abdominal Aortic Aneurysms

Published: 06-03-2007

Last updated: 11-05-2024

To identify an AAA associated genes by a functional candidate gene approach. The identification of an AAA associated gene will have several impacts on this high prevalent disease:1. It will improve our understanding of the molecular pathways involved...

|                              |   |
|------------------------------|---|
| <b>Ethical review</b>        | Approved WMO                              |
| <b>Status</b>                | Recruitment stopped                       |
| <b>Health condition type</b> | Cardiac and vascular disorders congenital |
| <b>Study type</b>            | Observational invasive                    |

## Summary

### ID

NL-OMON34059

### Source

ToetsingOnline

### Brief title

Genetics of Abdominal Aortic Aneurysms

### Condition

- Cardiac and vascular disorders congenital
- Aneurysms and artery dissections

### Synonym

aneurysm of the abdominal aorta / enlargement of the aorta

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Universitair Medisch Centrum Utrecht

**Source(s) of monetary or material Support:** Ministerie van OC&W, Nederlandse hartstichting, Novartis

## Intervention

**Keyword:** Abdominal Aortic Aneurysm, Association study, Genetics, Single Nucleotide Polymorphism

## Outcome measures

### Primary outcome

Difference in genetic profile between AAA patients and controls.

### Secondary outcome

Effect of genetic variants on RNA level.

## Study description

### Background summary

Aneurysms of the abdominal aorta (AAA) develop frequently in smoking, elderly males. Rupture of an AAA has a mortality rate of 85%. Therefore, AAAs are considered for surgery when they exceed the 55 mm diameter threshold that marks the borderline from which on the risk of rupture is superior to the mortality risk of surgery. There are 2 surgical options for an AAA, the conventional open repair and the endovascular treatment. The Dutch Randomised Endovascular Aneurysm Management (DREAM) trial was recently initiated in order to determine which procedure is superior. However, AAAs are usually asymptomatic and are therefore often not diagnosed. Randomised trials have indicated that ultrasound screening is effective in reducing AAA-related mortality, but before this screening is implemented in the clinical routine a high-risk population needs to be defined in detail. A family history of AAAs is the main risk factor for AAA development, with odds ratios varying from 4.1 to 9.7. In 3 Dutch families, with 4 or 5 affected siblings, a locus on chromosome 19q13.3 was described with a logarithm of odds (LOD) score of 3.95. This region contains approximately 250 genes. Based on the pathophysiology of AAAs, disease associated genes can encode inflammatory, immune, and extracellular matrix related proteins. We were therefore able to reduce the 250 genes of the 19q13.3 region to 12 functional candidate genes, and we aim to test the tagging SNPs of these genes to cover all the underlying genetic variation.

Additionally, genome wide association studies can scan the entire genome for SNPs that predispose to AAA formation.

The effects of the genetic variants can be studied in the RNA by investigating differences in expression levels or splicing between AAA cases and controls.

## Study objective

To identify an AAA associated genes by a functional candidate gene approach.

The identification of an AAA associated gene will have several impacts on this high prevalent disease:

1. It will improve our understanding of the molecular pathways involved in the development of AAAs. The processes that induce and promote AAA formation, like extracellular matrix reduction, inflammatory and immune responses, are well known. However, the main molecular players in these events are still elusive. Finding AAA predisposing SNPs in a certain gene will reveal the involvement of the encoded protein. Future studies, like transcription profiling and functional assays, may then further elucidate the molecular mechanisms.
2. It will allow defining a high risk group, which offers the possibility to:
  - a. perform more effective screening strategies
  - b. design prevention therapies for this group, that are based on the improved knowledge of the molecular mechanisms involved in the development of AAAs.
3. To study the effects of genetic variants on RNA level.

## Study design

1. Compare genetic profile of 650 AAA patients with that of 650 healthy age-sex matched controls. Specifically, tagging SNPs of candidate genes in the 19q13.3 region will be tested.
2. We will generate Genome wide association data of 1000 AAA patients and compare this to the genotype data of 2000 controls (from the NBS), The most promising SNPs will be tested in an additional cohort of 500 AAA pateints and 1000 controls.
3. We will study the effects of genetic variants on RNA level by comparing expression levels and splicing between cases and controls. RNA of at least 100 control samples is available in our laboratory.

## Study burden and risks

Minimal burden and risk, once blood withdrawel (30 ml)

## Contacts

### Public

Universitair Medisch Centrum Utrecht

Heidelberglaan 100  
3584 CX Utrecht  
Nederland  
**Scientific**  
Universitair Medisch Centrum Utrecht

Heidelberglaan 100  
3584 CX Utrecht  
Nederland

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

Aneurysm of the abdominal aorta of > 30 mm

### Exclusion criteria

no aneurysm

## Study design

### Design

Study type: Observational invasive

Intervention model: Other

Allocation: Non-randomized controlled trial

Masking: Open (masking not used)

**Primary purpose:** Basic science

## Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 25-04-2007

Enrollment: 1500

Type: Actual

## Ethics review

Approved WMO

Date: 06-03-2007

Application type: First submission

Review commission: METC Universitair Medisch Centrum Utrecht (Utrecht)

Approved WMO

Date: 28-07-2009

Application type: Amendment

Review commission: METC Universitair Medisch Centrum Utrecht (Utrecht)

Approved WMO

Date: 18-08-2009

Application type: Amendment

Review commission: METC Universitair Medisch Centrum Utrecht (Utrecht)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

### Register

CCMO

### ID

NL13835.041.06